Stockhub

Summit Therapeutics Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

14 August 2022

10 August 2022

  • curprev 01:5101:51, 10 August 2022‎ 109.180.50.163 talk‎ 722 bytes +722‎ Created page with "Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug res..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Summit_Therapeutics_Inc.’